BACKGROUND: The clinical significance of occult hepatitis B virus (HBV) infection, defined as the presence of HBV DNA in individuals with HBV core antibodies (anti-HBc) in the absence of HBV surface antigen (HBsAg), is unclear in HIV-infected patients. This information is needed to determine the importance of detecting and treating occult HBV in this population. OBJECTIVE: To determine if HIV-infected patients with occult HBV infection have an increased incidence of transaminitis. STUDY DESIGN: We performed a cohort study among randomly selected HBsAg-/anti-HBc+ HIV-infected patients in the Penn CFAR Database and Specimen Repository. HBV DNA was qualitatively detected using a transcription-mediated amplification assay. Hepatic transaminase levels, the main study outcome, were collected at 6-month intervals from the time of occult HBV determination. RESULTS: Among 97 randomly selected subjects without baseline transaminitis, 13 (13%) had occult HBV. These subjects more frequently had detectable HIV RNA. The 2-year incidence of transaminitis among HIV-infected subjects with occult HBV (50 events/100 person-years) was not significantly different from those without occult HBV (38 events/100 person-years; adjusted incidence rate ratio=1.36 [95% CI, 0.72-2.59]). CONCLUSIONS: Occult HBV did not increase the incidence of hepatic transaminitis over 2 years. Future studies should determine whether occult HBV is associated with other clinically important outcomes, particularly hepatocellular carcinoma.
BACKGROUND: The clinical significance of occult hepatitis B virus (HBV) infection, defined as the presence of HBV DNA in individuals with HBV core antibodies (anti-HBc) in the absence of HBV surface antigen (HBsAg), is unclear in HIV-infectedpatients. This information is needed to determine the importance of detecting and treating occult HBV in this population. OBJECTIVE: To determine if HIV-infectedpatients with occult HBV infection have an increased incidence of transaminitis. STUDY DESIGN: We performed a cohort study among randomly selected HBsAg-/anti-HBc+ HIV-infectedpatients in the Penn CFAR Database and Specimen Repository. HBV DNA was qualitatively detected using a transcription-mediated amplification assay. Hepatic transaminase levels, the main study outcome, were collected at 6-month intervals from the time of occult HBV determination. RESULTS: Among 97 randomly selected subjects without baseline transaminitis, 13 (13%) had occult HBV. These subjects more frequently had detectable HIV RNA. The 2-year incidence of transaminitis among HIV-infected subjects with occult HBV (50 events/100 person-years) was not significantly different from those without occult HBV (38 events/100 person-years; adjusted incidence rate ratio=1.36 [95% CI, 0.72-2.59]). CONCLUSIONS: Occult HBV did not increase the incidence of hepatic transaminitis over 2 years. Future studies should determine whether occult HBV is associated with other clinically important outcomes, particularly hepatocellular carcinoma.
Authors: N De Maria; A Colantoni; L Friedlander; G Leandro; R Idilman; J Harig; D H Van Thiel Journal: Am J Gastroenterol Date: 2000-12 Impact factor: 10.864
Authors: S Kubo; A Tamori; K Ohba; T Shuto; T Yamamoto; H Tanaka; S Nishiguchi; K Wakasa; K Hirohashi; H Kinoshita Journal: Dig Dis Sci Date: 2001-11 Impact factor: 3.199
Authors: Vincent Lo Re; Ian Frank; Robert Gross; Janel Dockter; Jeffrey M Linnen; Cristina Giachetti; Pablo Tebas; John Stern; Marie Synnestvedt; A Russell Localio; Jay R Kostman; Brian L Strom Journal: J Acquir Immune Defic Syndr Date: 2007-03-01 Impact factor: 3.731
Authors: Debika Bhattacharya; Chi-Hong Tseng; Janet P Tate; Vincent Lo Re; Cynthia L Gibert; Adeel A Butt; Sheldon T Brown; Joseph K Lim; Maria C Rodriguez-Barradas; David Rimland; Erica Kaufman; Amy C Justice; Matthew Bidwell Goetz Journal: J Acquir Immune Defic Syndr Date: 2016-05-01 Impact factor: 3.731